2/27
01:12 pm
imnn
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
Low
Report
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
2/27
08:05 am
imnn
IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
Low
Report
IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
2/26
08:05 am
imnn
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
Medium
Report
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
2/20
07:17 pm
imnn
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 [Yahoo! Finance]
Medium
Report
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 [Yahoo! Finance]
2/20
08:30 am
imnn
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
Low
Report
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
2/19
10:11 am
imnn
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
Medium
Report
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
2/19
08:05 am
imnn
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
Low
Report
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
2/10
08:05 am
imnn
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
Low
Report
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
2/10
07:18 am
imnn
Doxorubicin Global Industry Report 2025 - Doxorubicin Market Projected to Reach US$1.7 Billion by 2030 [Yahoo! Finance]
Low
Report
Doxorubicin Global Industry Report 2025 - Doxorubicin Market Projected to Reach US$1.7 Billion by 2030 [Yahoo! Finance]
1/24
09:16 am
imnn
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
Low
Report
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
12/19
12:17 pm
imnn
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
12/19
08:43 am
imnn
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
Low
Report
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
12/19
08:15 am
imnn
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer [Yahoo! Finance]
Low
Report
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer [Yahoo! Finance]
12/19
08:05 am
imnn
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
Low
Report
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer